Activity of combination abacavir/amprenavir/efavirenz therapy in HIV-1 infected subjects failing their current protease inhibitor containing regimen

被引：0
|
作者：
Eron, J
Falloon, J
Masur, H
Ait-Khaled, M
Thomas, D
Manion, D
Rogers, M
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] NIAID, NIH, Bethesda, MD 20892 USA
[3] Glaxo Wellcome Inc, Stevenage, Herts, England
[4] Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA
[5] DuPont Pharmaceut, Wilmington, DE USA
来源：
AIDS | 1998年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
OP52
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [1] Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity
    Falloon, J
    Piscitelli, S
    Vogel, S
    Sadler, B
    Mitsuya, H
    Kavlick, MF
    Yoshimura, K
    Rogers, M
    LaFon, S
    Manion, DJ
    Lane, HC
    Masur, H
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 (02) : 313 - 318
  • [2] Genotypic patterns of protease gene mutations and its correlation with plasma viremia in HIV-1 infected subjects failing a protease inhibitor containing regimen
    Bertelli, D
    Casari, S
    Barni, C
    Roldan, EQ
    Gagliotti, C
    Cadeo, GP
    [J]. AIDS, 2000, 14 : S120 - S120
  • [3] Ritonavir (RTV)/Amprenavir (APV) combination therapy in HIV infected patients who failed several protease inhibitor containing regimen
    Katlama, C
    Schneider, L
    Agher, R
    Delaugerre, C
    Calvez, V
    Legrand, M
    Tubiana, R
    [J]. AIDS, 2000, 14 : S28 - S28
  • [4] Efficacy and safety of the combination of efavirenz and abacavir in HIV-infected patients failing antiretroviral therapy
    Tenorio, AR
    Irlanda, IE
    Narkiewicz, E
    Smith, KY
    Kessler, HA
    Sha, BE
    [J]. AIDS, 2000, 14 (10) : 1470 - 1471
  • [5] Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
    Swindells, S
    Cohen, CJ
    Berger, DS
    Tashima, KT
    Liao, QM
    Pobiner, BF
    Snidow, JW
    Pakes, GE
    Hernandez, JE
    [J]. BMC INFECTIOUS DISEASES, 2005, 5 (1)
  • [6] Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
    Susan Swindells
    Calvin J Cohen
    Daniel S Berger
    Karen T Tashima
    Qiming Liao
    Bonnie F Pobiner
    Jerry W Snidow
    Gary E Pakes
    Jaime E Hernandez
    [J]. BMC Infectious Diseases, 5
  • [7] Phenotypic and genotypic resistance to a new protease inhibitor, 640385, in HIV-1 virus samples from subjects failing amprenavir
    Florance, A
    Elston, R
    Johnson, M
    Spreen, W
    St Clair, M
    [J]. ANTIVIRAL THERAPY, 2004, 9 (04) : U28 - U28
  • [8] Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults
    McMahon, D
    Lederman, M
    Haas, DW
    Haubrich, R
    Stanford, J
    Cooney, E
    Horton, J
    Kelleher, D
    Ross, L
    Cutrell, A
    Lee, D
    Spreen, W
    Mellors, JW
    [J]. ANTIVIRAL THERAPY, 2001, 6 (02) : 105 - 114
  • [9] Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir
    Abgrall, Sophie
    Yeni, Patrick G.
    Bouchaud, Olivier
    Costagliola, Dominique
    [J]. AIDS, 2006, 20 (16) : 2099 - 2106
  • [10] Amprenavir - A protease inhibitor for the treatment of patients with HIV-1 infection
    Reddy, P
    Ross, J
    [J]. FORMULARY, 1999, 34 (07) : 567 - +
12345